Schering Clarinex Reditabs approved
Executive Summary
Schering-Plough's Clarinex Reditabs 5 mg clears FDA June 26 for treatment of allergy symptoms and chronic idiopathic urticaria. Product launch is "pending FDA approval of a quality control test revision, the supplement for which has already been submitted, and the build-up of sufficient inventories," the company said. Reditabs have been "approvable" since December (1"The Pink Sheet" Dec. 24, 2001, p. 34)...
You may also be interested in...
Schering Clarinex Approval Comes In Time For Big Spring Push
Schering-Plough has received approval for the Claritin successor Clarinex in time to permit a big market build-up for the spring allergy season
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.